

XX MPI; 2001-316444/33.  
DR N-PSDB; AAS07029.  
XX New polypeptides derived from Streptococcus agalactiae are useful to  
PT provide detection of, and vaccination against, Group B Streptococcus  
PT infections, particularly to prevent infection in neonates.  
XX  
XX Claim 1, Fig 1, 178pp, English.  
XX  
XX AAU03601-AAU03722 represent Group B Streptococcus (Streptococcus  
CC agalactiae) amino acid sequences of the invention. S. agalactiae is an  
CC encapsulated bacterium which is a major pathogen of humans causing sepsis  
CC and meningitis in neonates as well as adults. The S. agalactiae antigenic  
CC polypeptides are used to vaccinate against Group B Streptococcus  
CC infections, particularly to prevent infection in new born children  
CC arising from the maternal genital tract. An immunogenic composition is  
CC useful in the preparation of a medicament for the treatment of  
CC prophylaxis of Group B Streptococcus infection. The invention does not  
CC have the disadvantages of varied response rate associated with prior art  
CC capsid polysaccharide vaccination against Group B Streptococcus  
XX  
XX Sequence 1055 AA;  
SQ  
Query Match 74.4%; Score 3777.5; DB 4; Length 1055;  
Best Local Similarity 71.7%; Pred. No. 1.7e-221;  
Matches 756; Conservative 105; Mismatches 140; Indels 53; Gaps 5;  
QY 2 KKHLLKVALTLTVSVVTHNQEVSLVKEPIKQTOASSISGADYAESGSKLKNET 61  
DB 3 KKHLLKVALTLTVSVVTHNQEVSLVKEPIKQTOASSISGADYAESGSKLKNET 61  
QY 62 SGVPDVTVDLPSDKTTPBKIKONIAKAPREGELAVTENT-ESERKQITSGSLEQSK 120  
DB 62 NSTVDETVSDLPSDGNSSSKTESVSDPKQVPRAKEVTOEASNSNDASKVEVPKQ 121  
QY 121 SLSLKTVPSTSNWEICDPTITKNTIVGSKSGVRLSCQDHYVLSQADGQQLQVNS 180  
DB 122 DTASKKETLETSTWEKMDPVTRGDTLVGFSKSGINTLSQTSHTVLPSSHADGQLQVNS 181  
QY 181 PAFTPDKTALAEYTSRAGENGISQLDVQKKEINIEGEPFNSYLLKVTYITPGYHIGQ 240  
DB 182 PAFTPDKTALAEYTSRAGENGISQLDVQKKEINIEGEPFNSYLLKVTYITPGYHIGQ 241  
QY 241 DAFVDMKNIAEVLPESELTISDPAFAHLAKQIDLPDLKALGELAFDNOQTGKLSIP 300  
DB 242 DAFVDMKNIAEVLPESELTISDPAFAHLAKQIDLPDLKALGELAFDNOQTGKLSIP 301  
QY 301 ROLMRLAERAPKSNHITKTEFRGNSLKVYGEASFQNDLSQMLPDGLKESBEATGNP 360  
DB 302 RHIIKIAERAPKSNHITKTEFRGNSLKVYGEASFQNDLSQMLPDGLKESBEATGNP 361  
QY 361 GDDHYNNRVVLMTKSGKPSGLATENTYVNPDKSLQOSBEIDTYMLSEDFYQKNSVT 420  
DB 362 GDBHTNNRVVLMTKSGKPSGLATENTYVNPDKSLQOSBEIDTYMLSEDFYQKNSVT 421  
QY 421 GFSNKGLOKVKRNKLEIPKOHGVITTEIGDPAFVNDPQNTLAKYDLEEVKLPSTR 480  
DB 422 GFSNKGLOKVKRNKLEIPKOHGVITTEIGDPAFVNDPQNTLAKYDLEEVKLPSTR 481  
QY 481 KTDAPFQSNNTKSPFASDLDLEIKEGAFNNRIETLELKDCLVTTGDAAPHNHITVAV 540  
DB 482 KTDAPFQSNNTKSPFASDLDLEIKEGAFNNRIETLELKDCLVTTGDAAPHNHITVAV 541  
QY 541 LPESVQIGRSAPRQGANLIPMGSKVTYIGEMAFSLNRLLEHLDLSEKOLTEIPVOAF 600  
DB 542 LPESVQIGRSAPRQGANLIPMGSKVTYIGEMAFSLNRLLEHLDLSEKOLTEIPVOAF 601  
QY 601 SDNALKEVLLPALSKTIREBAFQKNHKLQLEVASALSHIAFNALDNDNDGBOFQDNKVVYK 660  
DB 602 SDNALKEVLLPALSKTIREBAFQKNHKLQLEVASALSHIAFNALDNDNDGBOFQDNKVVYK 661  
QY 661 THHNSYALADGHEFIVDPDKLSTIVDLKILKLGIDYSLTRQTTQTQOFDMTTAGKA 720

DB 662 THHNSYALADGHEFIVDPDKLSTIVDLKILKLGIDYSLTRQTTQTQOFDMTTAGKA 721  
QY 721 LLSKSNLROGEKQKFLQBAQFLGRVDLKAJAKAKALVTKATNGOLLERSINKAVL 760  
DB 722 LLSKSNLROGEKQKFLQBAQFLGRVDLKAJAKAKALVTKATNGOLLERSINKAVL 761  
QY 761 AYNSNAIKKANVRLKEKEDLLTGVEGSGPLAQAATMVGVTLLKTPPLPBYTIGLVY 840  
DB 762 AYNSNAIKKANVRLKEKEDLLTGVEGSGPLAQAATMVGVTLLKTPPLPBYTIGLVY 841  
QY 841 PKSGGLIYALMSPDTIGEGQDAQGNPILANDENEGYHAALAVATLADYEGDITKILN 900  
DB 842 PKSGGLIYALMSPDTIGEGQDAQGNPILANDENEGYHAALAVATLADYEGDITKILN 901  
QY 901 SKLSQTSIRQVPTAAYHAGIFQALONAAABABQLLPQGTSEKSSSSSEANSKQDGL 960  
DB 902 SLSDKIKAIKQPLAKYHRLGIFQALIRNAAABABDRLLPK-----TPKGYLKEVPYRKQGM 957  
QY 961 QSNPK-----TN-----RGHSA 973  
DB 958 EKRLKEVDYKTPDIPNKALPNEKVDGPRAAKGNINATNNSVAVTPDIRSEQLHKSSQSDV 1017  
QY 974 ILPRGSGSFYVGIIGYTSVALLSLITAIKXKK 1007  
DB 1018 NLPQTSKNNPFIIEILGVSLCLLFLVYAGKGG 1051  
RESULT 5  
ABP56257  
ID ABP56257 standard; protein; 1055 AA.  
XX  
XX ABP56257;  
AC  
XX  
XX 28-MAR-2003 (first entry)  
DT  
XX  
XX Serotype III group B Streptococcus strain COH1 BVH-A4 SEQ ID NO:2.  
DE  
XX  
XX Serotype III group B Streptococcus strain COH1; BVH-A4; streptococcus;  
KW antibiotic; immunostimulant; vaccine; bacterial infection; sepsis;  
KW meningitis; pneumonia; cellulitis; osteomyelitis; septic arthritis;  
KW endocarditis; epiglottitis; osteomyelitis; amicitis; endometritis;  
KW cellulitis; fasciitis; bacteraemia; urosepsis; peritonitis; emphysema;  
KW mastitis; streptococcal infection.  
XX  
XX Streptococcus sp.  
OS  
XX  
XX  
FH Key Location/Qualifiers  
FT Peptide 1..52 /label= signal  
FT Protein 23..1055 /label= BVH-A4  
FT  
XX  
XX WO200286178-A2.  
PN  
XX  
XX 07-NOV-2002.  
PD  
XX  
XX 02-MAY-2002; 2002WO-CA000664.  
PF  
XX  
XX 02-MAY-2001; 2001US-0287712P.  
PR  
XX  
XX (SHIR-) SHIRE BIOCHEM INC.  
PA  
XX  
XX Martin D, Hamel J, Brodeur BR, Rioux S, Boyer M;  
PI MPI: 2003-120461/11.  
DR N-PSDB; ABZ21973.  
XX  
XX New BVH-A4 proteins and genes from serotype III group B streptococcus,  
PT useful for treating or preventing streptococcal infection in infants,  
PT pregnant women, non-pregnant adults (e.g. pneumonia), or members of dairy  
PT herd (mastitis).  
XX

RU Proc. Natl. Acad. Sci. U.S.A. 91:1019-1022, 1994.  
 DR EMBL: AE010019; AAL97553.1; -.  
 DR GO: GO:0009866; C:cell surface; IEA.  
 DR InterPro: IPR001899; Gram\_pos\_anchor.  
 DR InterPro: IPR007093; LRR\_Tp.  
 DR PROSITE: PS50847; GRAM\_POS\_ANCHORING, 1.  
 DR Complete proteome, Hypothetical protein  
 KW